DK0473687T3 - Stabilt lægemiddel indeholdende 3-(hydroxymethyl)-5,5-diphenylhydantoin-dinatriumphosphatester - Google Patents

Stabilt lægemiddel indeholdende 3-(hydroxymethyl)-5,5-diphenylhydantoin-dinatriumphosphatester

Info

Publication number
DK0473687T3
DK0473687T3 DK90908752.0T DK90908752T DK0473687T3 DK 0473687 T3 DK0473687 T3 DK 0473687T3 DK 90908752 T DK90908752 T DK 90908752T DK 0473687 T3 DK0473687 T3 DK 0473687T3
Authority
DK
Denmark
Prior art keywords
hydroxymethyl
phosphate ester
disodium phosphate
diphenylhydantoin
phenytoin
Prior art date
Application number
DK90908752.0T
Other languages
English (en)
Inventor
Dale E Herbranson
Earl R Speicher
Leonard S Rosenberg
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Application granted granted Critical
Publication of DK0473687T3 publication Critical patent/DK0473687T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Dental Preparations (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK90908752.0T 1989-05-25 1990-05-24 Stabilt lægemiddel indeholdende 3-(hydroxymethyl)-5,5-diphenylhydantoin-dinatriumphosphatester DK0473687T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/356,948 US4925860A (en) 1987-08-05 1989-05-25 Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester

Publications (1)

Publication Number Publication Date
DK0473687T3 true DK0473687T3 (da) 1996-08-05

Family

ID=23403641

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90908752.0T DK0473687T3 (da) 1989-05-25 1990-05-24 Stabilt lægemiddel indeholdende 3-(hydroxymethyl)-5,5-diphenylhydantoin-dinatriumphosphatester

Country Status (28)

Country Link
US (1) US4925860A (da)
EP (1) EP0473687B1 (da)
JP (1) JP3143471B2 (da)
KR (1) KR0143768B1 (da)
AT (1) ATE135907T1 (da)
AU (1) AU632130B2 (da)
CA (1) CA2067122A1 (da)
CZ (1) CZ277918B6 (da)
DE (2) DE69026253T2 (da)
DK (1) DK0473687T3 (da)
ES (1) ES2086404T3 (da)
FI (1) FI101041B (da)
HK (1) HK1006807A1 (da)
HU (1) HU212944B (da)
IE (1) IE81130B1 (da)
IL (1) IL94504A (da)
LU (1) LU90340I2 (da)
MX (1) MX9203584A (da)
MY (1) MY106190A (da)
NL (1) NL980045I2 (da)
NO (1) NO179124C (da)
NZ (1) NZ233808A (da)
PT (1) PT94161B (da)
RU (1) RU2075973C1 (da)
SG (1) SG64881A1 (da)
SK (1) SK277911B6 (da)
WO (1) WO1990014080A1 (da)
ZA (1) ZA904038B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU624262B2 (en) * 1989-08-10 1992-06-04 Warner-Lambert Company Use of prophenytoin for treating stroke
ES2169375T3 (es) * 1996-04-30 2002-07-01 Warner Lambert Co Proceso mejorado para la sintesis de diesteres del ester 2,5-dioxo-4,4-difenil-imidazolidin-1-ilmetilico de acido fosforico.
WO1998056422A1 (en) * 1997-06-13 1998-12-17 The University Of Kansas Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof
WO1999004798A1 (en) * 1997-07-22 1999-02-04 Warner-Lambert Company Lyophilized fosphenytoin sodium for parenteral use
US6110499A (en) * 1997-07-24 2000-08-29 Alza Corporation Phenytoin therapy
EP1153010A1 (en) 1999-02-08 2001-11-14 Checkpoint Genetics, Inc. $i(N)-SUBSTITUTED AMINO ACIDS, ANTIOXIDANT PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS USING SAME
WO2001000191A2 (en) * 1999-06-23 2001-01-04 Warner-Lambert Company Use of fosphenytion for the treatment of acute neuropathic pain
US20060034910A1 (en) * 2004-08-09 2006-02-16 Sanjay Patel Pharmaceutical composition for extended release of phenytoin sodium
US20070244074A1 (en) * 2006-04-17 2007-10-18 Sougata Pramanick Stable parenteral formulation of fosphenytoin sodium
KR101303088B1 (ko) * 2009-02-17 2013-09-06 한림제약(주) 3-(히드록시메틸)-5,5-디페닐히단토인 이나트륨 포스페이트에스테르를 함유하는 주사용 약학 조성물
ES3031438T3 (en) 2009-06-25 2025-07-08 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
CA2937222C (en) 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
WO2011163594A2 (en) 2010-06-24 2011-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9034867B2 (en) 2011-03-18 2015-05-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
UY34072A (es) 2011-05-17 2013-01-03 Novartis Ag Derivados sustituidos de indol
WO2013088255A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
WO2013142198A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
EP3718536A1 (en) 2012-09-19 2020-10-07 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN103288877B (zh) * 2013-05-10 2016-03-09 安徽省先锋制药有限公司 磷苯妥英稳定的有机胺盐及其制备方法和用途
EP3119399A4 (en) 2014-03-20 2017-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
JP7720391B2 (ja) 2020-12-04 2025-08-07 シーチュアン クレジット ファーマシューティカル カンパニー リミテッド フォスフェニトインナトリウム固体組成物、凍結乾燥法、及びその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260769A (en) * 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins

Also Published As

Publication number Publication date
EP0473687A4 (en) 1992-12-02
SK277911B6 (en) 1995-07-11
CZ277918B6 (en) 1993-06-16
NO179124B (no) 1996-05-06
RU2075973C1 (ru) 1997-03-27
NO914582D0 (no) 1991-11-22
HUT61198A (en) 1992-12-28
NL980045I2 (nl) 1999-07-01
WO1990014080A1 (en) 1990-11-29
CA2067122A1 (en) 1990-11-26
DE19975021I2 (de) 2004-07-01
HK1006807A1 (en) 1999-03-19
DE69026253T2 (de) 1996-09-19
NO179124C (no) 1996-08-14
MX9203584A (es) 1992-07-01
SG64881A1 (en) 1999-11-16
EP0473687B1 (en) 1996-03-27
NO914582L (no) 1991-11-22
JP3143471B2 (ja) 2001-03-07
ES2086404T3 (es) 1996-07-01
KR920700628A (ko) 1992-08-10
CS9002566A2 (en) 1991-10-15
IE81130B1 (en) 2000-03-22
ATE135907T1 (de) 1996-04-15
KR0143768B1 (ko) 1998-07-15
PT94161A (pt) 1991-01-08
NZ233808A (en) 1992-04-28
HU212944B (en) 1996-12-30
IL94504A (en) 1994-06-24
LU90340I2 (fr) 1999-03-19
IL94504A0 (en) 1991-03-10
AU5670490A (en) 1990-12-18
MY106190A (en) 1995-03-31
ZA904038B (en) 1992-01-29
PT94161B (pt) 1996-12-31
FI101041B (fi) 1998-04-15
FI915491A0 (fi) 1991-11-21
JPH05504544A (ja) 1993-07-15
DE69026253D1 (en) 1996-05-02
IE901872L (en) 1990-11-25
EP0473687A1 (en) 1992-03-11
NL980045I1 (nl) 1999-03-01
AU632130B2 (en) 1992-12-17
US4925860A (en) 1990-05-15

Similar Documents

Publication Publication Date Title
IL94504A0 (en) Pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
GB8819110D0 (en) Antihypertensive drug & method for production
DE10075030I1 (de) Pharmazeutische Zusammensetzungen die geminale Diphosphonate enthalten
AU1876788A (en) Methylene phosphonoalkylphosphinates, pharmaceutical compositions , and methods for treating abnormal calcium and phosphate metabolism
AU7815791A (en) Heterocyclene derivatives
FR2559389B1 (fr) Procede pour la preparation de compositions pharmaceutiques a liberation soutenue, ayant une forte teneur en ingredient actif
AU6143794A (en) Use of riluzole for treating aids-related neural disorders
NO179671C (no) Substituerte cykloheksanderivater, anvendelse av disse for fremstilling av legemidler samt legemiddel for behandling type II diabetes og andre sykdommer
ATE173401T1 (de) Neue verwendung von 1-alpha-hydroxylierten-19-nor-vitamin-d-verbind ngen zur behandlung von psoriasis
ATE147265T1 (de) Verwendung von retinoiden zur umkehr glucocorticoid-induzierter hautatrophie
HU9201789D0 (en) Process for the production of substituted diamino-phtalimides and their analogues
NO303715B1 (no) Stabilt, vandig apparat
SE9300758D0 (sv) Process for the production of clavulanic acid
TR199700694T1 (xx) D vitamini t�revlerinin dermotolojik kullan�m�.
ATE99946T1 (de) Lagerstabile orale glucosaminsulfat-dosisformen und verfahren zu deren herstellung.
BE893492A (fr) Procede de preparation d'esters d'acides apovincaminiques, esters ainsi obtenus et compositions pharmaceutiques prepares avec ces esters
HUT70757A (en) Pharmaceutical compositions for treating skin disorders
SE8303399D0 (sv) Azo-bis-salicyl syra och salt derav, deras farmaceutiska beredning samt framstellning av syran
BR8804931A (pt) Processo para a producao de uma tetra-hidro-1,3,5-tiadiazin-4-ona,e,composicao inseticida
GR1001133B (el) Μέ?οδος παρασκευής στα?ερής σύν?εσης δινατρίου άλατος φωσφορικού εστέρος 3-(υδροξυμε?υλο)-5,5-διφαινυλουδαντοϊνης.
BR0013563A (pt) Preparação farmacêutica sólida, utilização de uma preparação farmacêutica e processo para a produção de uma preparação farmacêutica
IT1255471B (it) Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
NO914005D0 (no) Fremgangsmaate for fremstilling av vitamin d2-forbindelserog de tilsvarende alfa-hydroksylerte derivater